AI in Genomics Market To Cross USD 35,267.3 Million by 2033

Introduction

The global AI in Genomics market is projected to grow from USD 733.4 million in 2023 to approximately USD 35,267.3 million by 2033, boasting a compound annual growth rate (CAGR) of 47.3%. This growth is driven by AI’s capability to process and analyze vast amounts of genomic data efficiently, far beyond manual human capacity. AI enhances diagnostic processes and decision-making within healthcare, proving crucial in genomics where data volumes are exceptionally large.

AI’s role in clinical decision support systems marks a significant application within the genomics field. These systems leverage AI algorithms to analyze genetic data alongside other patient information, aiding healthcare professionals in making more accurate and timely medical decisions. For example, AI tools are employed to interpret complex genetic data, improving the diagnosis and treatment of genetically influenced diseases.

Further integration of AI into medical imaging revolutionizes the identification and treatment of genetic diseases. AI algorithms are increasingly used for analyzing medical images, allowing for the precise and early detection of genetic anomalies. The reliability of AI in medical imaging is underscored by numerous approvals from the U.S. Food and Drug Administration, highlighting its effectiveness and trustworthiness in clinical settings.

AI also significantly enhances patient safety by predicting potential health trajectories and optimizing treatments. It forecasts possible complications or genetic disorders, enabling early preventative measures or customized therapies that substantially improve patient outcomes. This predictive capability is pivotal in advancing personalized medicine, optimizing healthcare interventions before adverse conditions manifest.

Recent developments underscore the market’s dynamism and AI’s expanding role in genomics. In September 2023, Deep Genomics launched an AI-driven foundational model focused on RNA biology, enhancing the understanding of genetic material’s role in disease. December 2023 saw Microsoft collaborate with Genoox to integrate Microsoft Genomics’ Azure Cloud with Genoox’s advanced framework for Next-Generation DNA Sequencing (NGS), showcasing significant strides in cloud-based genomic analytics. These initiatives reflect the growing trust and application of AI technologies in the field of genomics, promising continued market expansion and innovation.

Key Takeaways

• The AI in Genomics market is projected to witness substantial growth, with its value estimated to increase from USD 733.4 Million in 2023 to approximately USD 35,267.3 Million by the year 2033.
• This growth is expected to occur at an impressive CAGR of 47.3% during the forecast period spanning from 2024 to 2033.
• In terms of market segmentation based on components, the software segment emerged as the dominant segment in 2023, accounting for 47.2% of the market share.
• Among the technology segments, machine learning stood out as the leading technology in 2023, capturing the largest market share.
• Functionality-wise, genome sequencing held the largest market share of 46.1% in 2023.
• The drug discovery and development application segment contributed the most to the market, with a market share exceeding 34.4%.
• End-users in the AI in Genomics market primarily comprised pharmaceutical and biotech companies, accounting for a substantial market share in 2023.
• Geographically, North America led the market by generating the highest revenue share, capturing 31.7% of the market in 2023.
• The National Human Genome Research Institute estimates that the data anticipated to be generated from genomics research over the next decade will range from 2 to 40 billion exabytes.
• Research published in the Proceedings of the National Academy of Sciences (PNAS) suggests that approximately 17.3% of adults, equivalent to 1 in 6 individuals, have genetic findings, with this proportion increasing to 11.5% (1 in 9 people) when combined with deep phenotyping data.

AI in Genomics Statistics

• Decrease in Genome Sequencing Cost: The price to sequence a genome has drastically reduced from about $300 million for the first one to now just $100.
• Diversity in Genomic Data in the U.S.: The All of Us project in the United States now has over 250,000 genomes, focusing on including a variety of racial and ethnic groups.
• UK Biobank’s Contribution: The UK Biobank is a significant initiative that shares a large amount of genomic data, providing valuable resources for research.
• Genomic Data vs. Other AI Domains: Despite millions of genomes available, it’s still less compared to billions of data points used in other AI domains like image recognition and natural language processing.
• AI in Genomics: Global firms are increasingly using AI to manage the vast data from genome sequencing, which can be around 100 terabytes per individual genome.

Emerging Trends

• Enhanced Diagnostic Capabilities with AI: Artificial Intelligence (AI) is revolutionizing genomic diagnostics by significantly enhancing the precision and speed of genetic data analysis. This advancement is particularly evident in the integration of AI with next-generation sequencing (NGS) technologies. Such integration facilitates a more efficient and detailed genetic analysis, which is crucial in various research areas including cancer and infectious diseases. This trend is not only improving diagnostic capabilities but also impacting predictive healthcare by providing deeper insights into genetic factors.
• Focus on Ethical AI Development: There’s an increasing emphasis on the development of transparent and ethical AI tools within the genomics field. The objective is to ensure responsible usage of these advanced technologies. Efforts are underway to make AI algorithms more interpretable and to eliminate biases in genomic data. Addressing these issues is essential for building trust and fostering equitable healthcare outcomes. This trend underscores the importance of ethics in the deployment of cutting-edge technologies in healthcare.
• AI-driven Personalized Medicine: AI is playing a pivotal role in the evolution of personalized medicine, using algorithms to customize treatments based on individual genetic profiles. This approach is revolutionizing patient care by enabling treatments that are precisely tailored to each individual’s genetic makeup. Such personalized interventions are proving to be more effective and specific, significantly advancing the capabilities of medical treatments and patient care management.
• Cross-disciplinary Applications of AI in Genomics: AI’s application in genomics is encouraging cross-disciplinary strategies, especially in integrating genomic data with other biological data types. This comprehensive approach provides a more in-depth understanding of diseases at the molecular level. By fostering a holistic view, AI is crucial in enhancing drug discovery processes and improving disease prediction models, paving the way for innovative healthcare solutions.
• Global Data Collaboration Enhanced by AI: AI is facilitating a trend towards global collaboration in the sharing of genomic data, which is critical for advancing global health initiatives. AI technologies are essential in managing and analyzing vast datasets from diverse populations, helping to uncover genetic factors of diseases on a worldwide scale. This global perspective is vital for developing targeted health interventions and understanding disease patterns across different demographics.

Use Cases

• Cancer Genomics: Artificial Intelligence (AI) plays a pivotal role in cancer research, particularly in identifying genetic mutations and forecasting the progression of the disease. This technology is instrumental in refining the development of tailored therapies. By processing extensive genomic data, AI enables medical professionals to determine the most effective treatment approaches tailored to individual patient profiles. This capability not only streamlines treatment strategies but also enhances the precision and effectiveness of cancer care.
• Infectious Disease Control: In the realm of public health, AI algorithms are vital for analyzing pathogen genomes to monitor and predict the spread of infectious diseases. This application is crucial for managing epidemics and developing preventive strategies against future outbreaks. By leveraging AI, health officials can gain insights into disease patterns and transmission dynamics, which are essential for timely and effective epidemic management.
• Agricultural Biotechnology: AI’s application extends to agricultural biotechnology, where it is used to boost crop resistance against diseases and pests through genetic enhancements. This technological intervention is critical for improving food security by ensuring healthier and more robust crop yields. AI-driven genetic research in agriculture helps in developing crops that are better equipped to thrive in challenging environmental conditions, thereby securing food resources globally.
• Microbial Genomics: In microbial genomics, AI tools are employed to explore the dynamics of microbial communities and their impacts across various environments. Understanding these microbial interactions is crucial for environmental health and can propel forward new biotechnological discoveries. AI facilitates a deeper understanding of microbial behavior and ecology, which could lead to innovative applications in environmental conservation and biotechnology sectors.
• Genetic Disease Research: AI is instrumental in detecting genetic patterns and anomalies that could lead to diseases. This technology is particularly valuable for diagnosing rare genetic disorders at an early stage, which significantly enhances the treatment possibilities and outcomes for patients. By identifying these genetic markers early, AI supports the medical community in developing more effective intervention strategies, thus improving patient care and health outcomes.

Recent Developments

• Intel and University of Pennsylvania Collaboration: Intel Labs and the Perelman School of Medicine at the University of Pennsylvania have completed a joint research study utilizing distributed machine learning AI approaches for diagnosing brain tumors across international hospitals and research laboratories as of December 2022..
• NVIDIA’s Partnership with MIT and Harvard’s Broad Institute: In September 2022, NVIDIA collaborated with MIT and Harvard’s Broad Institute to expedite genome analysis. This partnership focuses on integrating Clara Parabricks into Terra, developing advanced language models for targeted therapies, and enhancing deep learning for genomic analysis toolkit.
• Technological Advancements in Genome Sequencing: An explosion in bioinformatics data is challenging genome analysis pipelines, requiring accelerated computing, data science, and AI to efficiently analyze genome sequencing data. NVIDIA is at the forefront, enhancing genome sequencing analysis workflows through deep learning and other advanced computational methods, significantly reducing the time and increasing the accuracy of genomic data analysis.
• Funding and Investments in AI Genomics: TechCrunch reports a substantial investment by Amazon, putting another $2.75 billion into Anthropic AI as part of the current AI innovation wave. This move underscores the significant financial backing AI and genomics projects are receiving, indicating strong market confidence in the transformative potential of these technologies..
• Skyflow’s Series B Funding: Skyflow raised an additional $30 million in Series B funding, led by Khosla Ventures. This investment highlights the growing demand for privacy business solutions in the context of AI’s rapid development..
• Google.org’s Generative AI Accelerator Program: Google.org launched a $20 million generative AI accelerator program to support nonprofits developing technology that leverages generative AI. This initiative aims to foster innovative applications of AI in the nonprofit sector.

Key Players Analysis

IBM

IBM has established a strong presence in the AI in Genomics sector by utilizing its expertise in artificial intelligence to drive innovation and growth. As per the 2023 Annual Report, IBM is committed to enhancing its AI capabilities, particularly through its Watsonx platform, which is specifically designed to manage the entire lifecycle of AI for businesses, including genomics applications. This commitment is further substantiated by IBM’s significant investments in research and development, amounting to nearly $7 billion in 2023, highlighting its dedication to advancing AI technologies.

Microsoft Corporation

Microsoft Corporation leads the way in integrating artificial intelligence (AI) into the genomics field. They offer innovative services that empower researchers and clinicians to achieve faster, more efficient genomic data analysis and insights. The Microsoft Genomics service, which is part of their Healthcare NExT initiative, provides a cloud-based platform that supports genome sequencing and research. This service utilizes the Burrows-Wheeler Aligner (BWA) and the Genome Analysis Toolkit (GATK) to analyze genomic data, ensuring scalability, security, and compliance with health data standards such as ISO certification and HIPAA.

Microsoft’s collaboration with institutions like St. Jude Children’s Research Hospital highlights their commitment to facilitating global research collaborations to accelerate discoveries in pediatric cancer and other genetic diseases. The Genomics service is built on Microsoft’s Azure platform, which offers a robust infrastructure for the large-scale computational requirements of genomic data analysis. This enables researchers to manage, analyze, and share genomic information more effectively, leveraging Microsoft’s extensive network of data centers to meet data sovereignty and compliance requirements. The service is designed to be user-friendly, with an easy-to-use API for seamless integration into existing genomic analysis pipelines. This ensures that researchers can focus on their scientific inquiries rather than the complexities of data management.

NVIDIA Corporation

NVIDIA Corporation is making significant progress in the AI in Genomics industry by using its advanced computing technologies and deep learning capabilities to enhance genomics research and analysis. NVIDIA has introduced powerful tools like NVIDIA Parabricks, which allows genomic researchers to perform analysis workflows up to 80 times faster, helping to quickly identify genetic variants that may lead to diseases or can be used as targets for therapeutics.

The company’s integration of AI into genomics is transforming the field not only by accelerating whole genome sequencing analysis but also by improving the accuracy of these analyses, making both short and long-read sequencing platforms operate more efficiently. NVIDIA’s collaboration with biotech companies like PacBio has resulted in the development of new sequencing systems that can produce high-accuracy long reads, making it possible to sequence the human genome at scale for less than $1,000. This innovative approach helps deal with the massive data generated by genomics, addresses storage challenges, and optimizes computational processes for faster and more precise results. With these initiatives, NVIDIA is leading the way in the next generation of genomics, significantly impacting clinical workflows, drug discovery, and the broader healthcare and life sciences industries.

DEEP GENOMICS

Deep Genomics is revolutionizing drug development by leveraging artificial intelligence to navigate the complexities of RNA biology. Their AI platform excels at identifying novel therapeutic targets and evaluating numerous potential therapies to pinpoint the most promising candidates. In 2018, this platform began identifying targets related to RNA splicing defects, leading to the introduction of the first Foundation Model for RNA Biology, BigRNA, in 2023. Deep Genomics is now developing BigRNA+, aiming to tackle more complex genetic diseases by discovering new biology and genetic targets.

Data4Cure, Inc.

Data4Cure, Inc. utilizes the Biomedical Intelligence® Cloud to transform data into actionable insights for drug development. This platform supports pharmaceutical companies and research organizations in making critical decisions throughout the drug discovery process, employing bioinformatics, systems biology, machine learning, and natural language processing. Its CURIE Knowledge Graph™ integrates vast datasets and publications, facilitating a comprehensive understanding of disease mechanisms, target identification, and drug repositioning.

Freenome Holdings, Inc.

Freenome Holdings, Inc. has raised $254 million to advance its early cancer detection platform, focusing on colorectal and lung cancers using blood tests. This funding will enhance the development of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform. With support from leading investors including Roche, Freenome aims to make early cancer detection more convenient and accessible, leveraging its platform to develop non-invasive screening tools for early, treatable stages of cancer.

Thermo Fisher Scientific

Thermo Fisher Scientific is enhancing genetic research with artificial intelligence (AI) and automation, particularly in its microarray platform. These innovations aim to boost lab productivity by efficiently analyzing and interpreting vast amounts of genetic data. AI plays a crucial role in genomics for identifying genetic disorders and improving disease research. Thermo Fisher’s approach combines molecular assays with computational biology and machine learning to handle the complexity of genetic data, promising advancements in early genome reading and disease research.

Illumina, Inc.

Illumina, Inc. has developed PrimateAI-3D, an AI algorithm for predicting disease-causing genetic mutations with high accuracy, demonstrated in research published in Science. This advancement, leveraging deep neural network architectures, aims to enhance genetic risk prediction and drug target discovery, facilitating precision medicine and understanding complex genetic diseases.

SOPHiA GENETICS

SOPHiA GENETICS is revolutionizing AI-assisted medicine by integrating and analyzing healthcare-omics data from various modalities. Their mission focuses on breaking down data silos and utilizing machine learning to deliver actionable insights, ultimately aiming to enhance patient outcomes globally.

BenevolentAI

BenevolentAI utilizes AI to empower scientists in unveiling new insights from data, significantly accelerating innovation and the discovery of successful drugs. Their AI-enabled drug discovery engine, the Benevolent Platform™, leverages vast biomedical data to offer a multidimensional view of human biology across diseases, aiming to enhance the success rate of clinical developments.

Fabric Genomics

Fabric Genomics specializes in AI-driven genomic interpretation, helping clinical labs, hospital systems, and national sequencing programs harness next-generation sequencing (NGS) data for precise diagnostics and treatments. Their technology is recognized for best-in-class accuracy and scalability in analyzing whole genomes, exomes, and targeted panels for various conditions, including rare diseases, hereditary risks, and cancers.

Conclusion

The Genomics market is on the brink of significant growth in Artificial Intelligence (AI), driven by technological advancements, a growing need for personalized medicine, and considerable investments in research and development. However, this growth will present its set of challenges, requiring innovative solutions and collaborations across the scientific community to utilize the potential of AI in genomics fully.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF